Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill amends 21 U.S.C. 355(q) (citizen petitions) to limit the use of citizen petitions as a tool to delay approval of generic drug and biosimilar applications. It requires a petitioner to submit a citizen petition (and any supplement) before filing a civil action challenging an ANDA, 505(b)(2) application, or a 351(k) biosimilar application, and to file the petition within 180 days after the petitioner knew the information forming the basis of the petition.
Progressives emphasize risks to safety oversight, public‑interest petitions, and the chilling effect of 180‑day timeliness and dismissal with prejudice; conservatives emphasize stopping tactical delays and speeding market competition.
Relative to its intended legislative type, this bill is a focused substantive amendment to 21 U.S.C. 355(q) that meaningfully reshapes the legal process around citizen petitions affecting generic and biosimilar approvals.
This bill amends 21 U.S.C. 355(q) (citizen petitions) to limit the use of citizen petitions as a tool to delay approval of generic drug and biosimilar applications.
It requires a petitioner to submit a citizen petition (and any supplement) before filing a civil action challenging an ANDA, 505(b)(2) application, or a 351(k) biosimilar application, and to file the petition within 180 days after the petitioner knew the information forming the basis of the petition.
The bill directs the Secretary of HHS (FDA) to consider a non‑exclusive list of factors when deciding whether a petition’s primary purpose was to delay approval and allows the Secretary to publish guidance describing additional factors.
Content alone places this bill in the 'moderate' likelihood range: it is a targeted, administratively-focused reform with limited fiscal impact and potential bipartisan appeal because it addresses timely access to generics. However, it alters procedural rights and litigation pathways and touches a well-funded industry, which creates potential opposition and legal scrutiny. Its success would depend largely on stakeholder bargaining, committee action, and whether provisions are softened in the legislative process.
Relative to its intended legislative type, this bill is a focused substantive amendment to 21 U.S.C. 355(q) that meaningfully reshapes the legal process around citizen petitions affecting generic and biosimilar approvals. It is precise in statutory drafting and integration with existing law and anticipates multiple modes of abuse, but it leaves certain interpretive terms and additional implementation details to guidance and does not address fiscal or monitoring needs.
Progressives emphasize risks to safety oversight, public‑interest petitions, and the chilling effect of 180‑day timeliness and dismissal with prejudice; conservatives emphasize stopping tactical delays and speeding market competition.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize risks to safety oversight, public‑interest petitions, and the chilling effect of 180‑day timeliness and dismissal with prejudice; conservatives emphasize stopping tactical delays and speeding mark…
A mainstream progressive would likely support the bill’s stated goal of faster access to lower‑cost generics and biosimilars but be worried that the new procedural bars could limit legitimate safety and public‑interest challenges.
They would be concerned the 180‑day deadline and the threat of dismissal with prejudice could chill whistleblowers, patient advocates, or public health groups from raising late‑arising safety or labeling concerns.
They would want clear safeguards to preserve FDA’s ability to act on genuine safety information and to protect public‑interest petitions and transparency.
A pragmatic moderate would view the bill as a reasonable effort to curb abusive delay tactics while recognizing the need to preserve legitimate safety oversight.
They would appreciate clearer procedure and timelines that reduce gamesmanship, but they would be cautious about strict time bars and automatic dismissal rules that may be inflexible.
They would look for implementation details and safeguards to ensure the policy doesn’t create unintended harms or litigation over process rather than merits.
A mainstream conservative would likely welcome this bill as a needed check on abusive citizen petitions that delay market entry of generics and biosimilars.
They would emphasize the benefits of speeding competition, reducing regulatory and litigation barriers, and preventing tactical delays by brand or other interest groups.
They would favor the procedural deadlines and dismissal rules as enforcing accountability and reducing regulatory capture via litigation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content alone places this bill in the 'moderate' likelihood range: it is a targeted, administratively-focused reform with limited fiscal impact and potential bipartisan appeal because it addresses timely access to generics. However, it alters procedural rights and litigation pathways and touches a well-funded industry, which creates potential opposition and legal scrutiny. Its success would depend largely on stakeholder bargaining, committee action, and whether provisions are softened in the legislative process.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize risks to safety oversight, public‑interest petitions, and the chilling effect of 180‑day timeliness and dismissal wi…
Content alone places this bill in the 'moderate' likelihood range: it is a targeted, administratively-focused reform with limited fiscal im…
Relative to its intended legislative type, this bill is a focused substantive amendment to 21 U.S.C. 355(q) that meaningfully reshapes the legal process around citizen petitions affecting generic and biosimilar approval…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.